Advertisement

Drugs

, Volume 57, Issue 1, pp 31–47 | Cite as

Second-Generation Antihistamines

A Comparative Review
  • James W. Slater
  • Andrew D. Zechnich
  • Dean G. Haxby
Review Article

Abstract

Second-generation histamine H1 receptor antagonists (antihistamines) have been developed to reduce or eliminate the sedation and anticholinergic adverse effects that occur with older H1 receptor antagonists. This article evaluates second-generation antihistamines, including acrivastine, astemizole, azelastine, cetirizine, ebastine, fexofenadine, ketotifen, loratadine, mizolastine and terfenadine, for significant features that affect choice.

In addition to their primary mechanism of antagonising histamine at the H1 receptor, these agents may act on other mediators of the allergic reaction. However, the clinical significance of activity beyond that mediated by histamine H1 receptor antagonism has yet to be demonstrated.

Most of the agents reviewed are metabolised by the liver to active metabolites that play a significant role in their effect. Conditions that result in accumulation of astemizole, ebastine and terfenadine may prolong the QT interval and result in torsade de pointes. The remaining agents reviewed do not appear to have this risk. For allergic rhinitis, all agents are effective and the choice should be based on other factors. For urticaria, cetirizine and mizolastine demonstrate superior suppression of wheal and flare at the dosages recommended by the manufacturer.

For atopic dermatitis, as adjunctive therapy to reduce pruritus, cetirizine, ketotifen and loratadine demonstrate efficacy. Although current evidence does not suggest a primary role for these agents in the management of asthma, it does support their use for asthmatic patients when there is coexisting allergic rhinitis, dermatitis or urticaria.

Keywords

Atopic Dermatitis Allergic Rhinitis Allergy Clin Immunol Terfenadine Cetirizine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Passalacqua G, Bousquet J, Bachert C, et al. The clinical safety of H1-receptor antagonists: an EAACI position paper. Allergy 1996 Oct; 51(10): 666–75PubMedGoogle Scholar
  2. 2.
    Woodward JK. Pharmacology of antihistamines. J Allergy Clin Immunol 1990 Oct; 86 (4 Pt 2): 606–12PubMedCrossRefGoogle Scholar
  3. 3.
    Marone G. Milestones in the biology and pharmacology of H1-receptor antagonists. Allergy 1997; 52 (34 Suppl.): 7–13PubMedCrossRefGoogle Scholar
  4. 4.
    Index Nominum: International Drug Directory [computer program]. Windows version. Swiss Pharmaceutical Society:medpharm, Sci Pub 1994–1998. Englewood (CO): MicromedexGoogle Scholar
  5. 5.
    Simons FE, Simons KJ. Pharmacokinetic optimisation of histamine H1-receptor antagonist therapy. Clin Pharmacokinet 1991 Nov; 21(5): 372–93PubMedCrossRefGoogle Scholar
  6. 6.
    Desager JP, Horsmans Y. Pharmacokinetic-pharmacodynamic relationships of H1-antihistamines. Clin Pharmacokinet 1995 May; 28(5): 419–32PubMedCrossRefGoogle Scholar
  7. 7.
    White MV. The role of histamine in allergic diseases. J Allergy Clin Immunol 1990 Oct; 86 (4 Pt 2): 599–605PubMedCrossRefGoogle Scholar
  8. 8.
    Rimmer SJ, Church MK. The pharmacology and mechanisms of action of histamine Hi-antagonists. Clin Exp Allergy 1990 Aug; 20 Suppl. 2: 3–17PubMedCrossRefGoogle Scholar
  9. 9.
    Casale TB. The interaction of azelastine with human lung histamine H1, beta, and muscarinic receptor-binding sites. J Allergy Clin Immunol 1989 Apr; 83(4): 771–6PubMedCrossRefGoogle Scholar
  10. 10.
    van Wauwe JP, Goossens JG. Arabinogalactan- and dextran-induced ear inflammation in mice: differential inhibition by H1-antihistamines, 5-HT-serotonin antagonists and lipoxy-genase blockers. Agents Actions 1989 Aug; 28(1-2): 78–82PubMedCrossRefGoogle Scholar
  11. 11.
    Campoli-Richards DM, Buckley MM, Fitton A. Cetirizine: a review of its pharmacological properties and clinical potential in allergic rhinitis, pollen-induced asthma, and chronic urticaria. Drugs 1990 Nov; 40(5): 762–81PubMedCrossRefGoogle Scholar
  12. 12.
    Masuo M, Shimada T, Kitazawa T. Mechanism of inhibitory effects of azelastine on smooth muscle contraction. J Pharmacol Exp Ther 1992 Mar; 260(3): 1300–8PubMedGoogle Scholar
  13. 13.
    Naclerio RM. The effect of antihistamines on the immediate allergic response: a comparative review. Otolaryngol Head Neck Surg 1993 Jun; 108(6): 723–30PubMedGoogle Scholar
  14. 14.
    Eda R, Sugiyama H, Hopp RJ, et al. Effect of loratadine on human eosinophil function in vitro. Ann Allergy 1993 Oct; 71(4): 373–8PubMedGoogle Scholar
  15. 15.
    Okada C, Eda R, Miyagawa H, et al. Effect of cetirizine on human eosinophil Superoxide generation, eosinophil chemotaxis and eosinophil peroxidase in vitro. Int Arch Allergy Immunol 1994; 103(4): 384–90PubMedCrossRefGoogle Scholar
  16. 16.
    Eda R, Townley RG, Hopp RJ. Effect of terfenadine on human eosinophil and neutrophil chemotactic response and generation of Superoxide. Ann Allergy 1994 Aug; 73(2): 154–60PubMedGoogle Scholar
  17. 17.
    Benavides J, Schoemaker H, Dana C, et al. In vivo and in vitro interaction of the novel selective histamine H1 receptor antagonist mizolastine with H1 receptors in the rodent. Arzneimittel Forschung 1995 May; 45(5): 551–8PubMedGoogle Scholar
  18. 18.
    Roberts DJ. A preclinical overview of ebastine: studies on the pharmacological properties of a novel histamine H1 receptor antagonist. Drugs 1996; 52 Suppl. 1: 8–14PubMedCrossRefGoogle Scholar
  19. 19.
    Howarth PH. Histamine and asthma: an appraisal based on specific H1-receptor antagonism. Clin Exp Allergy 1990 Aug; 20 Suppl. 2: 31–41PubMedCrossRefGoogle Scholar
  20. 20.
    Raud J, Thorlacius J, Xie X, et al. Interactions between histamine and leukotrienes in the microcirculation: aspects of relevance to acute allergic inflammation. Ann N Y Acad Sci 1994 Nov 15; 744: 191–8PubMedCrossRefGoogle Scholar
  21. 21.
    Wasserfallen JB, Leuenberger P, Pecoud A. Effect of cetirizine, a new H1 antihistamine, on the early and late allergic reactions in a bronchial provocation test with allergen. J Allergy Clin Immunol 1993 Jun; 91(6): 1189–97PubMedCrossRefGoogle Scholar
  22. 22.
    Spector SL, Nicodemus CF, Corren J, et al. Comparison of the bronchodilatory effects of cetirizine, albuterol, and both together versus placebo in patients with mild-to-moderate asthma. J Allergy Clin Immunol 1995 Aug; 96(2): 174–81PubMedCrossRefGoogle Scholar
  23. 23.
    Malick A, Grant JA. Antihistamines in the treatment of asthma. Allergy 1997; 52 (34 Suppl.): 55–66PubMedCrossRefGoogle Scholar
  24. 24.
    Paton DM, Webster DR. Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). Clin Pharmacokinet 1985 Nov–Dec; 10(6): 477–97PubMedCrossRefGoogle Scholar
  25. 25.
    Simons FE, Simons KJ. The pharmacology and use of H1-receptor-antagonist drugs. N Engl J Med 1994 Jun 9; 330(23): 1663–70PubMedCrossRefGoogle Scholar
  26. 26.
    Du Buske LM. Clinical comparison of histamine H1-receptor antagonist drugs. J Allergy Clin Immunol 1996 Dec; 98 (6 Pt 3): S307–18PubMedCrossRefGoogle Scholar
  27. 27.
    Brogden RN, McTavish D. Acrivastine: a review of its pharmacological properties and therapeutic efficacy in allergic rhinitis, urticaria and related disorders. Drugs 1991 Jun; 41(6): 927–40PubMedCrossRefGoogle Scholar
  28. 28.
    Gibson JR, Manna VK. Salisbury J. Acrivastine: a review of its dermatopharmacology and clinical activity. J Int Med Res 1989; 17 Suppl. 2: 28B–34BGoogle Scholar
  29. 29.
    Richards DM, Brogden RN, Heel RC, et al. Astemizole: a review of its pharmacodynamic properties and therapeutic efficacy. Drugs 1984 Jul; 28(1): 38–61PubMedCrossRefGoogle Scholar
  30. 30.
    McTavish D, Sorkin EM. Azelastine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs 1989 Nov; 38(5): 778–800PubMedCrossRefGoogle Scholar
  31. 31.
    Matzke GR, Yeh J, Awni WM, et al. Pharmacokinetics of cetirizine in the elderly and patients with renal insufficiency. Ann Allergy 1987 Dec; 59 (6 Pt 2): 25–30PubMedGoogle Scholar
  32. 32.
    Yamaguchi T, Hashizume T, Matsuda M, et al. Pharmacokinetics of the Hi-receptor antagonist ebastine and its active metabolite carebastine in healthy subjects. Arzneimittel Forschung 1994 Jan; 44(1): 59–64PubMedGoogle Scholar
  33. 33.
    Markham A, Wagstaff AJ. Fexofenadine. Drugs 1998 Feb; 55(2): 269–274PubMedCrossRefGoogle Scholar
  34. 34.
    Grant SM, Goa KL, Fitton A, et al. Ketotifen: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma and allergic disorders. Drugs 1990 Sep; 40(3): 412–48PubMedCrossRefGoogle Scholar
  35. 35.
    Haria M, Fitton A, Peters DH. Loratadine: a reappraisal of its pharmacological properties and therapeutic use in allergic disorders. Drugs 1994 Oct; 48(4): 617–37PubMedCrossRefGoogle Scholar
  36. 36.
    Clissold SP, Sorkin EM, Goa KL. Loratadine: a preliminary review of its pharmacodynamic properties and therapeutic efficacy. Drugs 1989 Jan; 37(1): 42–57PubMedCrossRefGoogle Scholar
  37. 37.
    Pinquier JL, Caplain H, Cabanis MJ, et al. Inhibition of histamine-induced skin wheal and flare after 5 days of mizolastine. J Clin Pharmacol 1996 Jan; 36(1): 72–8PubMedGoogle Scholar
  38. 38.
    Rosenzweig P, Caplain H, Chaufour S, et al. Comparative wheal and flare study of mizolastine vs terfenadine, cetirizine, loratadine and placebo in healthy volunteers. Br J Clin Pharmacol 1995 Nov; 40(5): 459–65PubMedGoogle Scholar
  39. 39.
    McTavish D, Goa KL, Ferrill M. Terfenadine: an updated review of its pharmacological properties and therapeutic efficacy. Drugs 1990 Apr; 39(4): 552–74PubMedCrossRefGoogle Scholar
  40. 40.
    Sorkin EM, Heel RC. Terfenadine: a review of its pharmaco-dynamic properties and therapeutic efficacy. Drugs 1985 Jan; 29(1): 34–56PubMedCrossRefGoogle Scholar
  41. 41.
    Simons FE, Murray HE, Simons KJ. Quantitation of H1-receptor antagonists in skin and serum. J Allergy Clin Immunol 1995 Mar; 95(3): 759–64PubMedCrossRefGoogle Scholar
  42. 42.
    Hey JA, del Prado M, Kreutner W, et al. Cardiotoxic and drug interaction profile of the second generation antihistamines ebastine and terfenadine in an experimental animal model of torsade de pointes. Arzneimittel Forschung 1996 Feb; 46(2): 159–63PubMedGoogle Scholar
  43. 43.
    Simons FE. H1-receptor antagonists: does a dose-response relationship exist? Ann Allergy 1993 Dec; 71(6): 592–7PubMedGoogle Scholar
  44. 44.
    Juhlin L. A comparison of the pharmacodynamics of H1-receptor antagonists as assessed by the induced wheal-and-flare model. Allergy 1995; 50 (24 Suppl.): 24–30PubMedCrossRefGoogle Scholar
  45. 45.
    Frossard N, Melac M, Benabdesselam O, et al. Consistency of the efficacy of cetirizine and ebastine on skin reactivity. Ann Allergy Asthma Immunol 1998 Jan; 80(1): 61–5PubMedCrossRefGoogle Scholar
  46. 46.
    Nickelsen JA, Georgitis JW, Reisman RE. Lack of correlation between titers of serum allergen-specific IgE and symptoms in untreated patients with seasonal allergic rhinitis. J Allergy Clin Immunol 1986 Jan; 77 (1 Pt 1): 43–8PubMedCrossRefGoogle Scholar
  47. 47.
    Small P, Biskin N. Barrett D. Does nasal provocation play a role in the diagnosis and management of ragweed-induced allergic rhinitis? Ann Allergy 1992 Mar; 68(3): 274–8Google Scholar
  48. 48.
    Spector SL. The placebo effect is nothing to sneeze at. J Allergy Clin Immunol 1992 Dec; 90 (6 Pt 2): 1042–3PubMedCrossRefGoogle Scholar
  49. 49.
    Monroe EW. Nonsedating H1 antihistamines in chronic urticaria. Ann Allergy 1993 Dec; 71: 585–91PubMedGoogle Scholar
  50. 50.
    Henauer S, Hugonot L, Hugonot R, et al. Multi-centre double-blind comparison of terfenadine once daily versus twice daily in patients with hay fever. J Int Med Res 1987 Jul–Aug; 15(4): 212–23PubMedGoogle Scholar
  51. 51.
    Stern MA, Rosenberg RM, Smith R, et al. A comparative study of terfenadine at two dose levels in the management of hay-fever. Br J Clin Pract 1990 Sep; 44(9): 359–63PubMedGoogle Scholar
  52. 52.
    Rosario NA. Comparison of terfenadine once daily with terfenadine twice daily for the treatment of perennial allergic rhinitis. J Int Med Res 1991 Mar–Apr; 19(2): 112–20PubMedGoogle Scholar
  53. 53.
    Renton R, Fidler C, Rosenberg R. Multicenter, crossover study of the efficacy and tolerability of terfenadine, 120mg, versus cetirizine, 10mg, in perennial allergic rhinitis. Ann Allergy 1991 Oct; 67(4): 416–20PubMedGoogle Scholar
  54. 54.
    Day JH, Briscoe MP, Welsh A, et al. Onset of action, efficacy, and safety of a single dose of fexofenadine hydrochloride for ragweed allergy using an environmental exposure unit. Ann Allergy Asthma Immunol 1997 Dec; 79(6): 533–40PubMedCrossRefGoogle Scholar
  55. 55.
    Berstein DI, Schoenwetter WF, Nathan RA. et al. Efficacy and safety of fexofenadine hydrochloride for treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 1997 Nov; 79(5): 443–8Google Scholar
  56. 56.
    Simons FE, McMillan JL, Simons KJ. A double-blind, single-dose, crossover comparison of cetirizine, terfenadine, loratadine, astemizole, and chlorpheniramine versus placebo: suppressive effects on histamine-induced wheals and flares during 24 hours in normal subjects. J Allergy Clin Immunol 1990 Oct; 86 (4 Pt 1): 540–7PubMedCrossRefGoogle Scholar
  57. 57.
    DuBuske L. Dose-ranging comparative evaluation of cetirizine in patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 1995 Apr; 74(4): 345–54PubMedGoogle Scholar
  58. 58.
    Jobst S, vanden Wijngaart W, Schubert A, et al. Assessment of the efficacy and safety of three dose levels of cetirizine given once daily in children with perennial allergic rhinitis. Allergy 1994 Sep; 49(8): 598–604PubMedCrossRefGoogle Scholar
  59. 59.
    Pearlman D, Lumry WR, Winder JA, et al. Once-daily cetirizine effective in the treatment of seasonal allergic rhinitis in children aged 6 to 11 years: a randomized, double-blind, placebo-controlled study. Clin Pediatr (Phila) 1997 Apr; 36(4): 209–15CrossRefGoogle Scholar
  60. 60.
    Leynadier F, Bousquet J, Murrieta M, et al. Efficacy and safety of mizolastine in seasonal allergic rhinitis: the Rhinase Study Group. Ann Allergy Asthma Immunol 1996 Feb; 76(2): 163–8PubMedCrossRefGoogle Scholar
  61. 61.
    Simons FE, Watson WT, Simons KJ. Lack of subsensitivity to terfenadine during long-term terfenadine treatment. J Allergy Clin Immunol 1988 Dec; 82(6): 1068–75PubMedCrossRefGoogle Scholar
  62. 62.
    Bousquet J, Chanal I, Skassa-Brociek W, et al. Lack of sub-sensitivity to loratadine during long-term dosing during 12 weeks. J Allergy Clin Immunol 1990 Aug; 86(2): 248–53PubMedCrossRefGoogle Scholar
  63. 63.
    Bousquet J, Chanal I, Murrieta M, et al. Lack of subsensitivity to mizolastine over 8-week treatment. Allergy 1996 Apr; 51(4): 251–6PubMedGoogle Scholar
  64. 64.
    Spaeth J, Klimek L, Mosges R, et al. Sedation in allergic rhinitis is caused by the condition and not by antihistamine treatment. Allergy 1996 Dec; 51(12): 893–906PubMedGoogle Scholar
  65. 65.
    Hindmarch I. Psychometric aspects of antihistamines. Allergy 1995; 50 (24 Suppl.): 48–54PubMedCrossRefGoogle Scholar
  66. 66.
    Simons FE, Fraser TG, Reggin JD, et al. Individual differences in central nervous system response to antihistamines (H1-receptor antagonists). Ann Allergy Asthma Immunol 1995 Dec; 75 (6 Pt 1): 507–14PubMedGoogle Scholar
  67. 67.
    Moser L, Huther KJ, Koch-Weser J, et al. Effects of terfenadine and diphenhydramine alone or in combination with diazepam or alcohol on psychomotor performance and subjective feelings. Eur J Clin Pharmacol 1978 Dec 18; 14(6): 417–23PubMedCrossRefGoogle Scholar
  68. 68.
    Seidel WF, Cohen S, Bliwise NG, et al. Cetirizine effects on objective measures of daytime sleepiness and performance. Ann Allergy 1987 Dec; 59 (6 Pt 2): 58–62PubMedGoogle Scholar
  69. 69.
    Simons FE. H1-receptor antagonists: comparative tolerability and safety. Drug Saf 1994 May; 10(5): 350–80PubMedCrossRefGoogle Scholar
  70. 70.
    Nolen TM. Sedative effects of antihistamines: safety, performance, learning, and quality of life [discussion 2–3]. Clin Ther 1997 Jan–Feb; 19(1): 39–55PubMedCrossRefGoogle Scholar
  71. 71.
    Simons FE, Fraser TG, Reggin JD, et al. Comparison of the central nervous system effects produced by six H1-receptor antagonists. Clin Exp Allergy 1996 Sep; 26(9): 1092–7PubMedCrossRefGoogle Scholar
  72. 72.
    Cetirizine prescribing information. New York: Pfizer, 1997Google Scholar
  73. 73.
    Azelastine prescribing information. Cranberry (NJ): Wallace Laboratories, 1997Google Scholar
  74. 74.
    Eltze M, Mutschler E, Lambrecht G. Affinity profiles of pizotifen, ketotifen and other tricyclic antimuscarinics at muscarinic receptor subtypes Ml, M2 and M3. Eur J Pharmacol 1992 Feb 18; 211(3): 283–93PubMedCrossRefGoogle Scholar
  75. 75.
    Wihl JA, Petersen BN, Petersen LN, et al. Effect of the non-sedative Hi-receptor antagonist astemizole in perennial allergic and nonallergic rhinitis. J Allergy Clin Immunol 1985 Jun; 75(6): 720–7PubMedCrossRefGoogle Scholar
  76. 76.
    Kailasam V, Mathews KP. Controlled clinical assessment of astemizole in the treatment of chronic idiopathic urticaria and angioedema. J Am Acad Dermatol 1987 Apr; 16(4): 797–804PubMedCrossRefGoogle Scholar
  77. 77.
    Chervinsky P, Georgitis J, Banov C, et al. Once daily loratadine versus astemizole once daily. Ann Allergy 1994 Aug; 73(2): 109–13PubMedGoogle Scholar
  78. 78.
    Ulbrich E, Nowak H. Long-term multicentre study with azelastine in patients with intrinsic asthma. Arzneimittel Forschung 1990 Nov; 40(11): 1225–30PubMedGoogle Scholar
  79. 79.
    Craft TM. Torsade de pointes after astemizole overdose. BMJ (Clin Res Ed) 1986 Mar 8; 292(6521): 660CrossRefGoogle Scholar
  80. 80.
    Davies AJ, Harindra V, McEwan A, et al. Cardiotoxic effect with convulsions in terfenadine overdose. BMJ 1989 Feb 4; 298(6669): 325PubMedCrossRefGoogle Scholar
  81. 81.
    Monahan BP, Ferguson CL, Killeavy ES, et al. Torsades de pointes occurring in association with terfenadine use. JAMA 1990 Dec 5; 264(21): 2788–90PubMedCrossRefGoogle Scholar
  82. 82.
    MacConnell TJ, Stanners AJ. Torsades de pointes complicating treatment with terfenadine. BMJ 1991 Jun 15; 302(6790): 1469PubMedCrossRefGoogle Scholar
  83. 83.
    Zimmermann M, Duruz H, Guinand O, et al. Torsades de pointes after treatment with terfenadine and ketoconazole. Eur Heart J 1992 Jul; 13(7): 1002–3PubMedGoogle Scholar
  84. 84.
    Zechnich AD, Haxby DG. Drug interactions associated with terfenadine and related nonsedating antihistamines. West J Med 1996 Jan; 164(1): 68–9PubMedGoogle Scholar
  85. 85.
    Honig PK, Woosley RL, Zamani K, et al. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin Pharmacol Ther 1992 Sep; 52(3): 231–8PubMedCrossRefGoogle Scholar
  86. 86.
    Woosley RL, Chen Y, Freiman JP, et al. Mechanism of the cardiotoxic actions of terfenadine. JAMA 1993 Mar 24-31; 269(12): 1532–6PubMedCrossRefGoogle Scholar
  87. 87.
    Berul CI, Morad M. Regulation of potassium channels by nonsedating antihistamines. Circulation 1995 Apr 15; 91(8): 2220–5PubMedCrossRefGoogle Scholar
  88. 88.
    Woosley RL. Cardiac actions of antihistamines. Annu Rev Pharmacol Toxicol 1996; 36: 233–52PubMedCrossRefGoogle Scholar
  89. 89.
    Hey JA, del Prado M, Egan RW, et al. Terfenadine, astemizole, and ebastine produce QTc interval prolongation in an experimental model predictive of adverse clinical ECG effects [letter]. Ann Allergy Asthma Immunol 1996 May; 76(5): 476PubMedCrossRefGoogle Scholar
  90. 90.
    Hey JA, del Prado M, Sherwood J, et al. Comparative analysis of the cardiotoxicity proclivities of second generation antihistamines in an experimental model predictive of adverse clinical ECG effects [see comments]. Arzneimittel Forschung 1996 Feb; 46(2): 153–8PubMedGoogle Scholar
  91. 91.
    Slaughter RL, Edwards DJ. Recent advances: the cytochrome P450 enzymes. Ann Pharmacother 1995 Jun; 29(6): 619–24PubMedGoogle Scholar
  92. 92.
    Riesenman C. Antidepressant drug interactions and the cytochrome P450 system: a critical appraisal. Pharmacotherapy 1995 Nov; 15 (6 Pt 2): 84S–99SPubMedGoogle Scholar
  93. 93.
    Albengres E, Le Louet H, Tillement JP. Systemic antifungal agents: drug interactions of clinical significance. Drug Saf 1998 Feb; 18(2): 83–97PubMedCrossRefGoogle Scholar
  94. 94.
    Faber TS, Zehender M, Just H. Drug-induced torsade de pointes: incidence, management and prevention. Drug Saf 1994 Dec; 11(6): 463–76PubMedCrossRefGoogle Scholar
  95. 95.
    Astemizole prescribing information. Titusville (NJ): Janssen Pharmaceutica, 1997Google Scholar
  96. 96.
    Terfenadine prescribing information. Kansas City (MO): Hoechst Marion Roussel, 1996Google Scholar
  97. 97.
    Food and Drug Administration. Seldane labeling changes. FDA Talk Paper 1997; T97–47Google Scholar
  98. 98.
    Bedford TA, Rowbotham DJ. Cisapride: drug interactions of clinical significance. Drug Saf 1996 Sep; 15(3): 167–75PubMedCrossRefGoogle Scholar
  99. 99.
    Einarson A, Bailey B, Jung G, et al. Prospective controlled study of hydroxyzine and cetirizine in pregnancy. Ann Allergy Asthma Immunol 1997 Feb; 78(2): 183–6PubMedCrossRefGoogle Scholar
  100. 100.
    Hubert J, Radwanski E, Affrime MB, et al. Excretion of loratadine in human breast milk. J Clin Pharmacol 1988 Mar; 28(3): 234–9Google Scholar
  101. 101.
    Lucas Jr BD, Purdy CY, Scarim SK, et al. Terfenadine pharma-cokinetics in breast milk in lactating women. Clin Pharmacol Ther 1995 Apr; 57(4): 398–402PubMedCrossRefGoogle Scholar
  102. 102.
    Howarth PH, Holgate ST. Comparative trial of two non-sedative H1 antihistamines, terfenadine and astemizole, for hay fever. Thorax 1984 Sep; 39(9): 668–72PubMedCrossRefGoogle Scholar
  103. 103.
    Girard JP, Sommacal-Schopf D, Bigliardi P, et al. Double-blind comparison of astemizole, terfenadine and placebo in hay fever with special regard to onset of action. J Int Med Res 1985; 13(2): 102–8PubMedGoogle Scholar
  104. 104.
    Bruttmann G, Pedrali P. Loratadine (SCH29851) 40mg once daily versus terfenadine 60 mg twice daily in the treatment of seasonal allergic rhinitis. J Int Med Res 1987 Mar–Apr; 15(2): 63–70PubMedGoogle Scholar
  105. 105.
    Gutkowski A, Bedard P, Del Carpio J, et al. Comparison of the efficacy and safety of loratadine, terfenadine, and placebo in the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 1988 May; 81 (5 Pt 1): 902–7PubMedCrossRefGoogle Scholar
  106. 106.
    Del Carpio J, Kabbash L, Turenne Y, et al. Efficacy and safety of loratadine (10mg once daily), terfenadine (60mg twice daily), and placebo in the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 1989 Nov; 84 (5 Pt 1): 741–6CrossRefGoogle Scholar
  107. 107.
    Oei HD. Double-blind comparison of loratadine (SCH 29851), astemizole, and placebo in hay fever with special regard to onset of action. Ann Allergy 1988 Dec; 61(6): 436–9PubMedGoogle Scholar
  108. 108.
    Meltzer EO, Weiler JM, Widlitz MD. Comparative outdoor study of the efficacy, onset and duration of action, and safety of cetirizine, loratadine, and placebo for seasonal allergic rhinitis. J Allergy Clin Immunol 1996 Feb; 97(2): 617–26PubMedCrossRefGoogle Scholar
  109. 109.
    Day JD, Briscoe M, Widlitz MD. Cetirizine, loratadine or placebo in subjects with seasonal allergic rhinitis: effects after controlled ragweed pollen challenge in an environmental exposure unit. J Allergy Clin Immunol 1998 May; 101(5): 638–45PubMedCrossRefGoogle Scholar
  110. 110.
    Lockey RF, Widlitz MD, Mitchell DQ, et al. Comparative study of cetirizine and terfenadine versus placebo in the symptomatic management of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 1996 May; 76(5): 448–54PubMedCrossRefGoogle Scholar
  111. 111.
    Day JH, Briscoe MP, Clark RH, et al. Onset of action and efficacy of terfenadine, astemizole, cetirizine, and loratadine for the relief of symptoms of allergic rhinitis. Ann Allergy Asthma Immunol 1997 Aug; 79(2): 163–72PubMedCrossRefGoogle Scholar
  112. 112.
    Spector SL, Toshener D, Gay I, et al. Beneficial effects of propylene and polyethylene glycol and saline in the treatment of perennial rhinitis. Clin Allergy 1982 Mar; 12(2): 187–96PubMedCrossRefGoogle Scholar
  113. 113.
    Lemanske Jr RF. A review of the current guidelines for allergic rhinitis and asthma. J Allergy Clin Immunol 1998 Feb; 101 (2 Pt 2): S392–6PubMedCrossRefGoogle Scholar
  114. 114.
    International Rhinitis Management Working Group. International consensus report on the diagnosis and management of rhinitis. Allergy 1994; 49 (19 Suppl.): 1–34CrossRefGoogle Scholar
  115. 115.
    Rachellefsky GS. Pharmacologic management of allergic rhinitis. J Allergy Clin Immunol 1998 Feb; 101 (2 Pt 2): S367–9CrossRefGoogle Scholar
  116. 116.
    Weiner JM, Abramson MJ, Puy RM. Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomized controlled trials. BMJ 1998 Dec 12; 317: 1624–9PubMedCrossRefGoogle Scholar
  117. 117.
    Juniper EF, Guyatt GH, Ferrie PJ, et al. First-line treatment of seasonal (ragweed) rhinoconjunctivitis: a randomized management trial comparing a nasal steroid spray and a nonsedating antihistamine. Can Med Assoc J 1997 Apr; 156(8): 1123–31Google Scholar
  118. 118.
    Meltzer EO, Tyrell Jr RJ, Rich D, et al. A pharmacologic continuumin the treatment of rhinorrhea: the clinician as economist. J Allergy Clin Immunol 1995 May; 95 (5 Pt 2): 1147–52PubMedCrossRefGoogle Scholar
  119. 119.
    Meltzer EO. The prevalence and medical and economic impact of allergic rhinitis in the United States. J Allergy Clin Immunol 1997 Jun: 99 (6 Pt 2): S805–28PubMedGoogle Scholar
  120. 120.
    Boggs PB, Ellis CN, Grossman J, et al. Double-blind, placebo-controlled study of terfenadine and hydroxyzine in patients with chronic idiopathic urticaria. Ann Allergy 1989 Dec; 63 (6 Pt 2): 616–20PubMedGoogle Scholar
  121. 121.
    Kalivas J, Breneman D, Tharp M, et al. Urticaria: clinical efficacy of cetirizine in comparison with hydroxyzine and placebo. J Allergy Clin Immunol 1990 Dec; 86 (6 Pt 2): 1014–8PubMedCrossRefGoogle Scholar
  122. 122.
    Breneman D, Bronsky EA, Bruce S, et al. Cetirizine and astemizole therapy for chronic idiopathic urticaria: a double-blind, placebo-controlled, comparative trial. J Am Acad Dermatol 1995 Aug; 33 (2 Pt 1): 192–8PubMedCrossRefGoogle Scholar
  123. 123.
    Breneman DL. Cetirizine versus hydroxyzine and placebo on chronic idiopathic urticaria. Ann Pharmacother 1996 Oct; 30(10): 1075–9PubMedGoogle Scholar
  124. 124.
    Kalis B. Double-blind multicentre comparative study of ebastine, terfenadine and placebo in the treatment of chronic idiopathic urticaria in adults. Drugs 1996; 52 Suppl. 1: 30–4PubMedCrossRefGoogle Scholar
  125. 125.
    Salo OP, Harvey SG, Calthrop JG, et al. A comparison of acrivastine versus hydroxyzine and placebo in the treatment of chronic idiopathic urticaria. J Int Med Res 1989; 17 Suppl. 2: 18B–21BPubMedGoogle Scholar
  126. 126.
    Kobza-Black A, Aboobaker J, Gibson JR, et al. Acrivastine versus hydroxyzine in the treatment of cholinergic urticaria: a placebo-controlled study. Acta Derm Venereol 1988; 68(6): 541–4PubMedGoogle Scholar
  127. 127.
    van Joost T, Blog FB, Westerhof W, et al. A comparison of acrivastine versus terfenadine and placebo in the treatment of chronic idiopathic urticaria. J Int Med Res 1989; 17 Suppl. 2: 14B–7BPubMedGoogle Scholar
  128. 128.
    Ormerod AD. Urticaria: recognition, causes and treatment. Drugs 1994 Nov; 48(5): 717–30PubMedCrossRefGoogle Scholar
  129. 129.
    Juhlin L. Nonclassical clinical indications for H1-receptor antagonists in dermatology. Allergy 1995; 50 (24 Suppl.): 36–40PubMedCrossRefGoogle Scholar
  130. 130.
    Barata LT, Ying S, Meng Q, et al. IL-4 and IL-5-positive T lymphocytes, eosinophils, and mast cells in allergen-induced late-phase cutaneous reactions in atopic subjects. J Allergy Clin Immunol 1998 Feb; 101 (2 Pt 1): 222–30PubMedCrossRefGoogle Scholar
  131. 131.
    Hannuksela M, Kalimo K, Lammintausta K, et al. Dose ranging study: cetirizine in the treatment of atopic dermatitis in adults. Ann Allergy 1993 Feb; 70(2): 127–33PubMedGoogle Scholar
  132. 132.
    La Rosa M, Ranno C, Musarra I, et al. Double-blind study of cetirizine in atopic eczema in children. Ann Allergy 1994 Aug; 73(2): 117–22PubMedGoogle Scholar
  133. 133.
    Yoshida H, Nimura M, Ueda H, et al. Clinical evaluation of ketotifen syrup on atopic dermatitis: a comparative multicenter double-blind study of ketotifen and clemastine. Ann Allergy 1989 Jun; 62(6): 507–12PubMedGoogle Scholar
  134. 134.
    Falk ES. Ketotifen in the treament of atopic dermatitis: results of a double blind study. Riv Eur Sci Med Farmacol 1993 Mar; 15(2): 63–6PubMedGoogle Scholar
  135. 135.
    Monroe EW. Relative efficacy and safety of loratadine, hydroxyzine, and placebo in chronic idiopathic urticaria and atopic dermatitis. Clin Ther 1992 Jan–Feb; 14(1): 17–21PubMedGoogle Scholar
  136. 136.
    Langeland T, Fagertun HE, Larsen S. Therapeutic effect of loratadine on pruritus in patients with atopic dermatitis: a multi-crossover-designed study. Allergy 1994 Jan; 49(1): 22–6PubMedCrossRefGoogle Scholar
  137. 137.
    Roquet A, Raud J, Hallden G, et al. Effects of loratadine on anti-IgE-induced inflammation, histamine release, and leukocyte recruitment in skin of atopics. Allergy 1995 May; 50(5): 414–20PubMedCrossRefGoogle Scholar
  138. 138.
    Brunijnzeel-Koomen C, Storz E, Menz G, et al. Skin eosinophilia in patients with allergic and nonallergic asthma and atopic dermatitis. J Allergy Clin Immunol 1992 Jan; 89 (1 Pt 1): 52–9CrossRefGoogle Scholar
  139. 139.
    Bruijnzeel PL, Kuijper PH, Rihs S, et al. Eosinophil migration in atopic dermatitis: increased migratory responses to N-formyl-methionyl-leucyl-phenylalanine, neutrophil-activating factor, platelet-activating factor, and platelet factor 4. J Invest Dermatol 1993 Feb; 100(2): 137–42PubMedCrossRefGoogle Scholar
  140. 140.
    Hoshiko K, Chapman ID, Morley J. Histamine (H1) antagonists and airway hyperreactivity in the guinea-pig. Agents Actions Suppl 1991; 34: 323–33PubMedGoogle Scholar
  141. 141.
    Levrier J, Duval D, Prouteau M, et al. Anti-anaphylactic activity of the novel selective histamine H1 receptor antagonist mizolastine in the rodent. Arzneimittel Forschung 1995 May; 45(5): 559–68PubMedGoogle Scholar
  142. 142.
    Berth-Jones J, Graham-Brown RA. Failure of terfenadine in relieving the pruritus of atopic dermatitis. Br J Dermatol 1989 Nov; 121(5): 635–7PubMedCrossRefGoogle Scholar
  143. 143.
    Wahlgren CF, Hagermark O, Bergstrom R. The antipruritic effect of a sedative and a non-sedative antihistamine in atopic dermatitis. Br J Dermatol 1990 Apr; 122(4): 545–51PubMedCrossRefGoogle Scholar
  144. 144.
    Leung DY, Hanifin JM, Charlesworth EN, et al. Disease management of atopic dermatitis: a practice parameter. Joint Task Force on Practice Parameters, representing the American Academy of Allergy, Asthma and Immunology, the American College of Allergy, Asthma and Immunology, and the Joint Council of Allergy, Asthma and Immunology. Work Group on Atopic Dermatitis. Ann Allergy Asthma Immunol 1997 Sep; 79(3): 197–211Google Scholar
  145. 145.
    Clee MD, Ingram CG, Reid PC, et al. The effect of astemizole on exercise-induced asthma. Br J Dis Chest 1984 Apr; 78(2): 180–3PubMedCrossRefGoogle Scholar
  146. 146.
    Patel KR. Terfenadine in exercise induced asthma. BMJ 1984 May 19; 288(6429): 1496–7PubMedCrossRefGoogle Scholar
  147. 147.
    Bentley AM, Walker S, Hanotte F, et al. A comparison of the effects of oral cetirizine and inhaled beclomethasone on early and late asthmatic responses to allergen and the associated increase in airways hyperresponsiveness. Clin Exp Allergy 1996 Aug; 26(8): 909–17PubMedCrossRefGoogle Scholar
  148. 148.
    Grant JA, Nicodemus CF, Findlay SR, et al. Cetirizine in patients with seasonal rhinitis and concomitant asthma: prospective, randomized, placebo-controlled trial. J Allergy Clin Immunol 1995 May; 95 (5 Pt 1): 923–32PubMedCrossRefGoogle Scholar
  149. 149.
    Aaronson DW. Evaluation of cetirizine in patients with allergic rhinitis and perennial asthma. Ann Allergy Asthma Immunol 1996 May; 76(5): 440–6PubMedCrossRefGoogle Scholar
  150. 150.
    Azelastine-Asthma Study Group. An evaluation of the efficacy and safety of azelastine in patients with chronic asthma. J Allergy Clin Immunol 1996 Jun; 97(6): 1218–24CrossRefGoogle Scholar
  151. 151.
    Canny GJ, Reisman J, Levison H. Does ketotifen have a steroid-sparing effect in childhood asthma? Eur Respir J 1997 Jan; 10(1): 65–70PubMedCrossRefGoogle Scholar
  152. 152.
    Hoshino M, Nakamura Y, Shin Z, et al. Effects of ketotifen on symptoms and on bronchial mucosa in patients with atopic asthma. Allergy 1997 Aug; 52(8): 814–20PubMedCrossRefGoogle Scholar
  153. 153.
    Aaronson DW. Side effects of rhinitis medications. J Allergy Clin Immunol 1998 Feb; 101 (2 Pt 2): S379–82PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1999

Authors and Affiliations

  • James W. Slater
    • 1
  • Andrew D. Zechnich
    • 2
  • Dean G. Haxby
    • 3
    • 4
  1. 1.College of PharmacyOregon State University and Oregon Health Sciences UniversityPortlandUSA
  2. 2.Department of Emergency MedicineOregon Health Sciences UniversityPortlandUSA
  3. 3.College of PharmacyOregon State UniversityPortlandUSA
  4. 4.Department of Family MedicineOregon Health Sciences UniversityPortlandUSA

Personalised recommendations